Unicycive Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Unicycive Therapeutics R&D Spending Growth & History (UNCY)
Unicycive Therapeutics's r&d spending was $9.1M for fiscal 2025.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.1M | −$10.9M | −54.43% |
| 2024 | 2024-12-31 | $20.0M | $7.1M | +55.12% |
| 2023 | 2023-12-31 | $12.9M | $466,000 | +3.75% |
| 2022 | 2022-12-31 | $12.4M | $6.4M | +104.54% |
| 2021 | 2021-12-31 | $6.1M | $5.1M | +499.01% |
| 2020 | 2020-12-31 | $1.0M | — | — |
Unicycive Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.8M | $1.0M | +59.31% |
| Q1 2026 | 2026-03-31 | $1.6M | −$564,000 | −25.98% |
| Q4 2025 | 2025-12-31 | $2.2M | −$3.1M | −57.72% |
| Q3 2025 | 2025-09-30 | $3.0M | −$81,000 | −2.66% |
| Q2 2025 | 2025-06-30 | $1.8M | −$3.1M | −64.05% |
| Q1 2025 | 2025-03-31 | $2.2M | −$4.6M | −68.13% |
| Q4 2024 | 2024-12-31 | $5.3M | $1.1M | +24.92% |
| Q3 2024 | 2024-09-30 | $3.0M | −$327,000 | −9.70% |
| Q2 2024 | 2024-06-30 | $4.9M | $2.6M | +114.73% |
| Q1 2024 | 2024-03-31 | $6.8M | $3.8M | +124.85% |
| Q4 2023 | 2023-12-31 | $4.2M | $393,000 | +10.23% |
| Q3 2023 | 2023-09-30 | $3.4M | −$1.4M | −29.79% |
| Q2 2023 | 2023-06-30 | $2.3M | $407,000 | +21.88% |
| Q1 2023 | 2023-03-31 | $3.0M | $1.1M | +56.75% |
| Q4 2022 | 2022-12-31 | $3.8M | $2.5M | +182.15% |
| Q3 2022 | 2022-09-30 | $4.8M | $1.0M | +27.20% |
| Q2 2022 | 2022-06-30 | $1.9M | $1.4M | +277.28% |
| Q1 2022 | 2022-03-31 | $1.9M | $1.5M | +329.56% |
| Q4 2021 | 2021-12-31 | $1.4M | — | — |
| Q3 2021 | 2021-09-30 | $3.8M | $3.5M | +1142.11% |
| Q2 2021 | 2021-06-30 | $493,000 | $311,000 | +170.88% |
| Q1 2021 | 2021-03-31 | $450,000 | — | — |
| Q3 2020 | 2020-09-30 | $304,000 | — | — |
| Q2 2020 | 2020-06-30 | $182,000 | — | — |
Unicycive Therapeutics r&d spending trends
Over the last five fiscal years, Unicycive Therapeutics's r&d spending increased from $1.0M to $9.1M, a change of $8.1M. The latest reported quarter, Q2 2026, shows $2.8M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Unicycive Therapeutics source filings ↗